Abstract：Objective To analyze the research hotspots and trends of traditional Chinese medicine for prevention and treatment of diabetic retinopathy. Methods Literatures on the prevention and treatment of diabetic retinopathy with traditional Chinese medicine were retrieved from CNKI database from inception to April 30, 2022, the number of articles published was analyzed. The author cooperation, institution cooperation, and keyword knowledge map were drawn and analyzed by CiteSpace 6.1.R1 software. Results A total of 1 722 literatures were included, and the number of annual publications showed an increasing trend; 821 authors were included in the author collaborative network map, and Duan Junguo was more influential; 596 institutions were included in the institutional collaborative network map, represented by Chengdu University of Traditional Chinese Medicine; the keyword knowledge map indicated that the pathogenesis, therapeutic drugs, traditional Chinese medicine syndrome types, and syndrome differentiation and treatmeat were the current research hotspots for traditional Chinese medicine to prevent and treatment diabetic retinopathy. Conclusion The prevention and treatment of diabetic retinopathy by traditional Chinese medicine has a great prospect of development. It may be the trend of future research to explore the role and mechanism of traditional Chinese medicine in the pathogenesis of diabetic retinopathy and to find and develop new therapeutic targets.
刘春 张丽萍 吴晓筱 段俊国. 基于中国知网的中医药防治糖尿病视网膜病变的CiteSpace知识图谱分析[J]. 中国医药导报, 2023, 20(6): 76-80.
LIU Chun ZHANG Liping WU Xiaoxiao DUAN Junguo. CiteSpace knowledge map analysis of traditional Chinese medicine prevention and treatment of diabetic retinopathy based on CNKI. 中国医药导报, 2023, 20(6): 76-80.
[1] Ting DSW，Cheung GCM，Wong TY. Diabetic retinopathy：global prevalence，major risk factors，screening practices and public health challenges：a review [J]. Clin Exp Ophthalmol，2016，44（4）：260-277.
[2] Cho NH，Shaw JE，Karuranga S，et al. IDF Diabetes Atlas：Global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract，2018，138：271- 281.
[3] 邓宇轩，叶雯青，孙艳婷，等.中国糖尿病视网膜病变患病率的荟萃分析[J].中华医学杂志，2020，100（48）：3846- 3852.
[4] 陈若瑜，曹丹，张良.糖尿病视网膜病变药物治疗研究进展[J].眼科新进展，2022，42（3）：244-248.
[5] Elkjaer AS，Lynge SK，Grauslund J. Evidence and indications for systemic treatment in diabetic retinopathy：a systematic review [J]. Acta ophthalmologica，2020，98（4）：329- 336.
[6] 范艳萍，李勇峰，陈国亮，等.芪明颗粒对非增殖期糖尿病视网膜病变的疗效及安全性评价[J].国际眼科杂志，2018，18（12）：2260-2263.
[7] 蒋鹏飞，李翔，彭俊，等.益气养阴，活血利水法治疗474例气阴两虚证糖尿病视网膜病变患者的回顾性分析[J].湖南中医药大学学报，2022，42（4）：685-688.
[8] 陈悦，陈超美，刘则渊，等.CiteSpace知识图谱的方法论功能[J].科学学研究，2015，33（2）：242-253.
[9] Chen C. Science Mapping：A Systematic Review of the Literature [J]. J Data Information Science，2017，2（2）：1-40.
[10] Sasongko MB，Wong TY，Jenkins AJ，et al. Circulating markers of inflammation and endothelial function，and their relationship to diabetic retinopathy [J]. Diabet Med，2015，32（5）：686-691.
[11] Stahel M，Becker M，Graf N，et al. Systemic interleukin 1β inhibition in proliferative diabetic retinopathy：a prospective open-label study using canakinumab [J]. Retina ，2016，36（2）：385-391.
[12] 孔慧，崔彦.CD40-ATP-P2X7/NLRP3炎症信号通路在糖尿病视网膜病变中的作用研究进展[J].眼科新进展，2021，41（9）：879-882，891.
[13] Kang Q，Yang C. Oxidative stress and diabetic retinopathy：Molecular mechanisms，pathogenetic role and therapeutic implications [J]. Redox Biology，2020，37：101799.
[14] Karbasforooshan H，Karimi G. The role of SIRT1 in diabetic retinopathy [J]. Biomed Pharmacother，2018，97：190-194.
[15] 贾鑫，刘英琳，杨赞章，等.止血明目方对糖尿病视网膜病变大鼠炎症因子和氧化应激的影响[J].中国中医眼科杂志，2022，32（4）：257-262.
[16] Filippov VM，Petrachkov DV，Budzinskaya MV，et al. Modern concepts of pathogenesis of diabetic retinopathy [J].Vestn Oftalmol，2021，137（5. Vyp. 2）：306-313.
[17] Hu Z，Mao X，Chen M，et al. Single-cell transcriptomics reveals novel role of microglia in fibrovascular membrane of proliferative diabetic retinopathy [J]. Diabetes，2022，71（4）：762-773.
[18] Mishra M，Kowluru RA. DNA methylation-a potential source of mitochondria dna base mismatch in the development of diabetic retinopathy [J]. Mol neurobiol，2019，56（1）：88- 101.
[19] 于乃馨，李国琼，李标，等.基于网络药理学和分子对接探讨黄芪甲苷治疗糖尿病视网膜病变的作用机制[J].中国实验方剂学杂志，2022，28（13）：209-216.
[20] 姜丽萍，庄晓林，吴庆峰，等.羟苯磺酸钙胶囊联合丹参注射液治疗老年2型糖尿病早期视网膜病变的临床疗效[J].中国临床药理学杂志，2017，33（14）：1304-1306.
[21] 李青春，邢怡桥，李岱.白藜芦醇对糖尿病大鼠视网膜Bcl-2和Bax表达的影响[J].实用医学杂志，2018，34（8）：1223-1226.
[22] 段俊国，廖品正，叶河江，等.治疗糖尿病视网膜病变中药新药芪明颗粒临床循证研究[C]//.2014浙江省眼科学术年会论文汇编，2014：46.
[23] 彭清华.糖尿病视网膜病变中西医结合研究现状[J].中国中西医结合杂志，2021，41（6）：660-662.
[24] 郑大海.廖品正中医眼科学术思想研究[D].广州：广州中医药大学，2017.
[25] 陈梅，曾志成，彭俊，等.益气养阴活血利水复方联合玻璃体腔注射康柏西普对糖尿病黄斑水肿患者玻璃体液 HIF-1α 和 VEGF 表达影响[J].中国中西医结合杂志，2020，40（2）：149-153.
[26] 彭清华，曾志成，彭俊，等.黄斑水肿的中医药治疗[J].中国中医眼科杂志，2020，30（6）：381-385.
京公网安备 11010502046598号